Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.80)
# 1,873
Out of 4,734 analysts
43
Total ratings
33.33%
Success rate
52.16%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.27 | +1,632.28% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $10.00 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $5.55 | +332.43% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $26.96 | +263.50% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $17.63 | +609.02% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.99 | +804.52% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $6.64 | +186.14% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $0.90 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $4.11 | +14,498.54% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $183.51 | -56.86% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $54.26 | +185.66% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.54 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.92 | +408.13% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $0.36 | +70,733.33% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $180 | $2.71 | +6,542.07% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $59.56 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.53 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $10.16 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.25 | +20,020.72% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.18 | +8,228.71% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.81 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $22.18 | +914.43% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $12.57 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $5.05 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.27
Upside: +1,632.28%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $10.00
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $5.55
Upside: +332.43%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $26.96
Upside: +263.50%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $17.63
Upside: +609.02%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.99
Upside: +804.52%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $6.64
Upside: +186.14%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.90
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $4.11
Upside: +14,498.54%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $183.51
Upside: -56.86%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $54.26
Upside: +185.66%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.54
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $4.92
Upside: +408.13%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $0.36
Upside: +70,733.33%
Mar 2, 2021
Initiates: Outperform
Price Target: $180
Current: $2.71
Upside: +6,542.07%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $59.56
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.53
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $10.16
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.25
Upside: +20,020.72%
Apr 8, 2020
Initiates: Outperform
Price Target: $15
Current: $0.18
Upside: +8,228.71%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.81
Upside: -
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $22.18
Upside: +914.43%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $12.57
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $5.05
Upside: -